NASDAQ Companies

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage […]

– Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant […]

– Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity […]

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered […]

Company Completes First Quarter Publicly-Traded on Nasdaq Global Market under “ATLN” Announces Strategic Developments and Outlook; Targets $1 to $1.5 […]

Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce […]

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that […]

CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as […]

FG-3246 showed encouraging anti-cancer activity with an acceptable safety profile in patients with metastatic castration-resistant prostate cancer Initiation of Phase […]

HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi […]